A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

Recruiting

PHASE2Ages 40+InterventionalTreatment

AstraZeneca

~359 participants

Updated 2026-06-25 on ClinicalTrials.gov

What's tested:Placebo for AZD8965AZD8965 low doseAZD8965 medium doseAZD8965 high dose

At a glance

Recruiting sites

4 of 190 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24

Measured over at Week 24

Idiopathic Pulmonary Fibrosis (IPF)

NCT07652658

This study runs at 190 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Research Site
Birmingham, Alabamano site contact published
Not yet recruiting
Research Site
Phoenix, Arizonano site contact published
Not yet recruiting
Research Site
Phoenix, Arizonano site contact published
Not yet recruiting
Research Site
Loma Linda, Californiano site contact published
Not yet recruiting
Research Site
Los Angeles, Californiano site contact published
Not yet recruiting
Research Site
Newport Beach, Californiano site contact published
Recruiting
Research Site
Sacramento, Californiano site contact published
Not yet recruiting
Research Site
Stanford, Californiano site contact published
Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

AstraZeneca Clinical Study Information Center

Opens a ready-to-send draft in your own email app — review before sending.

To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24at Week 24
To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24